Malignant News and Research

RSS

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

Presence of virus linked with malignant human prostate cancer cells

In a finding with potentially major implications for identifying a viral cause of prostate cancer, researchers at the University of Utah and Columbia University medical schools have reported that a type of virus known to cause leukemia and sarcomas in animals has been found for the first time in malignant human prostate cancer cells.

7 Sep 2009

Nanotubes destroy kidney tumors

By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.

7 Sep 2009

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

When bees sting, they pump into their victims a peptide toxin called melittin that destroys cell membranes. Now, by encapsulating this extremely potent molecule within a nanoparticle, researchers at the Washington University School of Medicine in St. Louis have created a potential new type of anticancer therapy with the potential to target a wide range of tumors. This work was reported in the Journal of Clinical Investigation.

7 Sep 2009

Five Clinical Research Units established

With the establishment of five new Clinical Research Units the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) hopes to give a further boost to clinical research in Germany and drive progress in the scientific investigation and possibilities for the treatment of disease.

7 Sep 2009

Identifying a specific molecular signature can help customize cancer treatment

A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.

7 Sep 2009

NCI renews SPORE grant for the diagnosis and treatment of ovarian cancer

National Cancer Institute (NCI) has renewed a $11.5 million Specialized Program of Research Excellence (SPORE) grant in prevention, diagnosis and treatment of ovarian cancer, which supports multidisciplinary research at Fox Chase Cancer Center and the University of Pennsylvania. First approved in 1999, this marks the third five-year term for the Fox Chase-Penn Ovarian SPORE.

4 Sep 2009

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.

3 Sep 2009

Patient perception of physician disclosure key to gaining trust

When reporting medical errors, patients' perceptions of their physicians' disclosure may be key to gaining their trust, according to researchers from the Johns Hopkins Bloomberg School of Public Health. However, a positive perception of the disclosure has little effect on the lawsuit risk a physician faces.

2 Sep 2009

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance. A "death receptor" can possibly provide information as to how great the chances of success are for chemotherapy. At the same time, it offers a new approach for promising brain tumor therapy.

2 Sep 2009

Altered gene network interaction plays an important role in brain tumors

The interaction between a network of altered genes appears to play an important role in the development and progression of brain tumors, according to a study in the July 15 issue of JAMA.

1 Sep 2009

New technique developed for the treatment of cancer

A new paradigm in the way we look at cancer with important implications on how we treat it is about to be published in the British Journal of Cancer by Portuguese, Belgian and American researchers.

1 Sep 2009

MabCure featured in the August edition of Biotechnology Focus magazine

MabCure, Inc. (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in the August edition of Biotechnology Focus, Canada's oldest and most successful magazine serving the Canadian life science industry.

31 Aug 2009

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

TomoTherapy Incorporated announced today that there will be more than 40 presentations at the 10th Biennial ESTRO Conference on Physics and Radiation Technology for Clinical Radiotherapy that explore use of the TomoTherapy treatment system. The TomoTherapy system -- a versatile, CT scanner-based device that integrates image guidance for increased treatment accuracy and helical radiation therapy delivery for enhanced tumor targeting -- is helping cancer centers advance patient care around the world.

28 Aug 2009

More than 22,000 Americans expected to be diagnosed with a malignant brain tumor in 2009

It is expected that more than 22,000 Americans will be diagnosed with a malignant brain tumor in 2009. Senator Ted Kennedy's death from a brain cancer draws attention to a rare, but often fatal type disease. While the risk of developing brain cancer is relatively low, it is important to heed the warning signs and receive an accurate diagnosis.

27 Aug 2009

FDA approves Supersonic Imagine's Aixplorer ultrasound system

SuperSonic Imagine today announced that it has received 510K Clearance from the FDA for its Aixplorer(TM) ultrasound system and will begin to market and deliver the device in the United States. Aixplorer is the only commercially available system of its kind with MultiWave(TM) Technology, which is based upon interaction between conventional longitudinal waves and shear waves in tissue.

26 Aug 2009

First patient enrolled for IDEV Technologies' SUPERB clinical trial

IDEV(R) Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that the first patient was enrolled in the Company's FDA-approved multi-center clinical trial of its self-expanding SUPERA(R) stent, a novel stent platform designed for the treatment of biliary and peripheral artery disease (PAD) in the superficial femoral artery (SFA).

25 Aug 2009

Combined therapy for acute leukemia shows promising results

Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.

25 Aug 2009

Study reveals factors associated with higher mortality rate in haematological malignancy

A study of 7,689 admissions from 178 adult intensive care unit s in England, Wales and Northern Ireland has revealed the factors associated with a higher mortality rate in haematological malignancy. Researchers writing in BioMed Central's open access journal Critical Care found that certain factors have a significant impact on the risk of death.

25 Aug 2009

Malignant News and Research

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

Presence of virus linked with malignant human prostate cancer cells

Nanotubes destroy kidney tumors

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

Five Clinical Research Units established

Identifying a specific molecular signature can help customize cancer treatment

NCI renews SPORE grant for the diagnosis and treatment of ovarian cancer

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Patient perception of physician disclosure key to gaining trust

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Altered gene network interaction plays an important role in brain tumors

New technique developed for the treatment of cancer

MabCure featured in the August edition of Biotechnology Focus magazine

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

More than 22,000 Americans expected to be diagnosed with a malignant brain tumor in 2009

FDA approves Supersonic Imagine's Aixplorer ultrasound system

First patient enrolled for IDEV Technologies' SUPERB clinical trial

Combined therapy for acute leukemia shows promising results

Study reveals factors associated with higher mortality rate in haematological malignancy

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News